Rubius Therapeutics (NASDAQ:RUBY) Vs. TWST, ADPT, SWTX, SANA, RLAY, RXRX, VALN, KYMR, IOVA, and TIL
Should you be buying Rubius Therapeutics stock or one of its competitors? The main competitors of Rubius Therapeutics include Twist Bioscience (TWST), Adaptive Biotechnologies (ADPT), SpringWorks Therapeutics (SWTX), Sana Biotechnology (SANA), Relay Therapeutics (RLAY), Recursion Pharmaceuticals (RXRX), Valneva (VALN), Kymera Therapeutics (KYMR), Iovance Biotherapeutics (IOVA), and Instil Bio (TIL). These companies are all part of the "biological products, except diagnostic" industry.
Rubius Therapeutics vs.
Adaptive Biotechnologies (NASDAQ:ADPT) and Rubius Therapeutics (NASDAQ:RUBY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, earnings, valuation, community ranking, profitability, risk and dividends.
Adaptive Biotechnologies currently has a consensus target price of $60.33, suggesting a potential upside of 137.07%. Rubius Therapeutics has a consensus target price of $26.33, suggesting a potential upside of 114.79%. Given Adaptive Biotechnologies' stronger consensus rating and higher possible upside, equities analysts plainly believe Adaptive Biotechnologies is more favorable than Rubius Therapeutics.
Adaptive Biotechnologies has higher revenue and earnings than Rubius Therapeutics. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Rubius Therapeutics, indicating that it is currently the more affordable of the two stocks.
Rubius Therapeutics has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -129.89%. Adaptive Biotechnologies' return on equity of -27.07% beat Rubius Therapeutics' return on equity.
Adaptive Biotechnologies has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500. Comparatively, Rubius Therapeutics has a beta of 2.38, indicating that its share price is 138% more volatile than the S&P 500.
In the previous week, Adaptive Biotechnologies and Adaptive Biotechnologies both had 3 articles in the media. Rubius Therapeutics' average media sentiment score of 0.30 beat Adaptive Biotechnologies' score of -0.38 indicating that Rubius Therapeutics is being referred to more favorably in the news media.
82.8% of Adaptive Biotechnologies shares are held by institutional investors. Comparatively, 95.1% of Rubius Therapeutics shares are held by institutional investors. 3.9% of Adaptive Biotechnologies shares are held by company insiders. Comparatively, 55.7% of Rubius Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Rubius Therapeutics received 89 more outperform votes than Adaptive Biotechnologies when rated by MarketBeat users. However, 62.79% of users gave Adaptive Biotechnologies an outperform vote while only 60.93% of users gave Rubius Therapeutics an outperform vote.
Summary
Adaptive Biotechnologies beats Rubius Therapeutics on 9 of the 16 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding RUBY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rubius Therapeutics (NASDAQ:RUBY) vs. Its Competitors
Rubius Therapeutics Competitors List
